Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Clinical trial NCT03580928 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03580928
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-07
- Primary completion
- 2024-04-10
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.